麻豆淫院

Research teams have created a versatile set of gene delivery systems that can reach different neural cell types in the human brain and spinal cord with exceptional accuracy. These delivery systems are a significant step toward future precise gene therapy for the brain that could safely control errant brain activity with high precision. In contrast, current therapies for brain disorders mostly treat only symptoms.

The new delivery systems carry genetic material into the brain and spinal cord for targeted use by specific cell types. This platform has the potential to transform how scientists can study neural circuits. It provides researchers with gene delivery systems for various species used in research, without the need for genetically modified, or transgenic, animals. Examples include illuminating fine structures of brain cells with fluorescent proteins and activating or silencing circuits that control behavior and cognition.

"Imagine this new platform as a delivery truck dropping off specialized genetic packages in specific cell neighborhoods in the brain and spinal cord," said John Ngai, Director of the NIH's Brain Research Through Advancing Innovative Neurotechnologies Initiative, or The BRAIN Initiative. "With these delivery systems, we can now access and manipulate specific cells in the brain and spinal cord鈥攁ccess that was not possible before at this scale."

The new delivery tools, which use a small, stripped-down adeno-associated virus (AAV) to deliver DNA to target cells, can be broadly applied across many species and experimental systems, including small tissue samples removed during human brain surgeries. The delivery systems have been tested, or validated, in intact living systems, which is an important step for introducing new tools for widespread use. The newly published toolkit includes:

• Dozens of delivery systems that selectively target key brain cell types, including excitatory neurons, inhibitory interneurons, striatal and cortical subtypes, brain blood vessel cells, and hard-to-reach neurons in the spinal cord that control body movement and are damaged in several neurological diseases, such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy.
• Computer programs powered by artificial intelligence (AI) that can identify genetic "light switches," known as enhancers, that turn genes on in specific brain cell types, using data from many different species鈥攃utting considerable time and effort for scientists looking for these genetic switches.

Overall, this collection of research tools will significantly accelerate our understanding of the human brain. Importantly, the toolkit enables access to specific brain cell types in the prefrontal cortex, an area that's critical for decision-making and uniquely human traits.

With other tools in the collection, scientists can better study individual cells and communication pathways known to be affected in several neurological diseases. These include seizure disorders, ALS, Parkinson's disease, Alzheimer's disease, and Huntington's disease鈥攁s well as various neuropsychiatric conditions.

AAV-based treatments are already approved for some conditions, such as spinal muscular atrophy for which a 2016 approval of a gene therapy known as Zolgensma transformed the lives of infants and young children who once faced severe disability or early death. The new collection of gene delivery resources lays the groundwork for more precise treatments that target only affected cells in the brain, spinal cord, or brain blood vessels.

The toolkit is available at distribution centers including , a global supplier of genetic research tools. This collection of publications offers researchers standard operating procedures and user guides for these tools.

The large-scale project brings together experts in the field of molecular biology, neuroscience, and artificial intelligence (AI). The that resulted from the initiative were published in the journals Neuron, Cell, Cell Reports, Cell Genomics, and Cell Reports Methods.